---
title: Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib
  Resistance and Pre-BCR<sup>+</sup> Acute Lymphoblastic Leukemia
date: '2023-09-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37686604/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230909181124&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'The multi-kinase inhibitor dasatinib has been implicated to be effective
  in pre-B-cell receptor (pre-BCR)-positive acute lymphoblastic leukemia (ALL) expressing
  the E2A-PBX1 fusion oncoprotein. The TGFβ signaling pathway is involved in a wide
  variety of cellular processes, including embryonic development and cell homeostasis,
  and it can have dual roles in cancer: suppressing tumor growth at early stages and
  mediating tumor progression at later stages. In this study, we identified ...'
disable_comments: true
---
The multi-kinase inhibitor dasatinib has been implicated to be effective in pre-B-cell receptor (pre-BCR)-positive acute lymphoblastic leukemia (ALL) expressing the E2A-PBX1 fusion oncoprotein. The TGFβ signaling pathway is involved in a wide variety of cellular processes, including embryonic development and cell homeostasis, and it can have dual roles in cancer: suppressing tumor growth at early stages and mediating tumor progression at later stages. In this study, we identified ...